Status:
NOT_YET_RECRUITING
Inturlekin L33 in Ankylosing Spondylities Patients and Its Relation to Subclinical Atherosclerosis
Lead Sponsor:
Assiut University
Conditions:
Ankylosing Spondylitis
Eligibility:
All Genders
20-40 years
Brief Summary
detect level of Inturlekin 33 in ankylosing spondyilits patient measure CIMT (carotid intima media thickness ) by carotid duplex to detect subclinical atherosclerosis in ankylosing spondyitis patient...
Detailed Description
Ankylosing spondylitis (AS), a type of SpA, is an autoimmune disease that mainly involves, sacroiliac joints (SIJs) and their adjacent soft tissues, such as tendons and ligaments. The main clinical ma...
Eligibility Criteria
Inclusion
- patient diagnosed as Ankylosing Spondylitis
- Age (20-40)
Exclusion
- Patients with other rheumatic diseases/other SPA types
- Participants with history of CVD event in past or present
- Patient experiencing cardiovascular revascularization surgery or cerebrovascular disorder within past 6 months.
- Patient with other risk factor for atherosclerosis.
Key Trial Info
Start Date :
September 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT06564155
Start Date
September 1 2024
End Date
December 1 2026
Last Update
August 22 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.